Table 3.
No | Bcell epitope | Position | Vaxijen Score | Allergenicity | Final decision |
---|---|---|---|---|---|
1 | SIDGKNYQQAVPGQEGGVRG | 142–161 | 1.6824 | No allergen | * |
2 | LNAEIRPWGASTNPWAQGLY | 98–117 | 0.1589 | Allergen | |
3 | KNWGVFGEVGAYYTGNPKVE | 183–202 | 0.0053 | Allergen | |
4 | GYNGGDISWTDDVSVNGTKY | 68–87 | 0.9330 | No allergen | * |
5 | APVTGNPTSAQDAVDKEANE | 209–228 | 1.1717 | No allergen | * |
6 | NQLIPVGARAEVGTTGYGGA | 35–54 | 0.8647 | No allergen | * |
7 | KNQLIPV | 34–40 | − 0.7431 | Allergen | |
8 | IRPWGASTNRWAQGL | 81–95 | 0.3082 | Allergen | |
9 | NVDATRSFRVNNQDFIAGADGV | 113–134 | 0.8684 | No allergen | * |
10 | FAPKINKNWGV | 154–164 | 0.7523 | No allergen | * |
11 | SGSAVTTGDQSLEEAVNA | 183–200 | 1.2565 | No allergen | * |
12 | DISWSDDVKVNGST | 52–65 | 1.2709 | No allergen | * |
13 | AMADEAVVHDSYAFDKNQLI | 19–38 | 0.0036 | Allergen | |
14 | GAAYLDNDYDLAKRIGNGDT | 121–140 | 0.3189 | Allergen | |
15 | WQANPYVGLALGYNGGDISW | 57–76 | 0.4059 | Allergen | |
16 | ACINETACTERAMANN | 15–30 | 0.5248 | No allergen | * |
17 | EVGAYYTGNPKVELTQ | 232–247 | 0.5643 | No allergen | * |
18 | RAEVGTTGYGGALLWQ | 85–100 | 0.9620 | No allergen | * |
19 | EAVVHDSYAFDKNQLI | 65–80 | − 0.1973 | Allergen | |
20 | GGDISWTDDVSVNGTK | 113–228 | 1.3248 | No allergen | * |
21 | DNKYEWMPVGKVGVNF | 274–289 | 0.1697 | Allergen | |
22 | PVTGNPTSAQDAVDKE | 252–267 | 1.1236 | No allergen | * |
23 | TQYNLAPVTGNPTSAQ | 246–261 | 0.8548 | Allergen | |
24 | GQEGGVRGKMSYKNDI | 196–211 | 1.9167 | Allergen |
Thirteen B-cell epitopes were selected (labeled with *) for selective step to incorporation in the vaccine construct